Drugs / PLT012
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07337525 | Feb 2026 → Sep 2027 expected | cancer | Pilatus Biosciences Inc | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLT012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07337525 ↗ |
| Modality | Monoclonal antibody | “PLT012 (anti-CD36 monoclonal antibody)” NCT07337525 ↗ |
| Route | Intravenous | “PLT012 administered via intravenous infusion once every 3 weeks” NCT07337525 ↗ |
| Target | CD36 | “PLT012 (anti-CD36 monoclonal antibody)” NCT07337525 ↗ |